SCHEMBL1009050

SCHEMBL1009050

CCOC(=O)Cc1cccc(OCc2cc(C)cc(C)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOB P27338 10/20 0.51
PPARA Q07869 2/20 0.50
PPARG P37231 1/20 0.50
LTB4R Q15722 1/20 0.49
LTB4R2 Q9NPC1 1/20 0.49
MAOA P21397 1/20 0.49
PARP10 Q53GL7 1/20 0.48
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
PKM P14618 1/20 0.45
NR1H4 Q96RI1 1/20 0.45
F10 P00742 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008116 0.89 LTB4R (0.61) MAOBPPARAPPARGLTB4RLTB4R2
SCHEMBL31285834 0.86 PPARA (0.57) MAOBPPARAPPARGLTB4RLTB4R2
SCHEMBL2008583 0.86 PPARA (0.57) MAOBPPARAPPARGLTB4RLTB4R2
SCHEMBL956767 0.85 MAOB (0.55) MAOBLTB4RLTB4R2MAOAPARP10
SCHEMBL1010327 0.84 SLC22A12 (0.50) MAOBPPARAPPARGLTB4RLTB4R2
SCHEMBL9270474 0.83 MAOB (0.59) MAOBPPARAPPARGLTB4RLTB4R2
SCHEMBL1009025 0.82 PPARA (0.46) MAOBPPARAPPARGLTB4RLTB4R2
SCHEMBL1009029 0.82 MAOB (0.52) MAOBPPARAPPARGLTB4RLTB4R2
SCHEMBL1008243 0.81 MAOB (0.61) MAOBPPARAPPARGLTB4RLTB4R2
SCHEMBL1107143 0.81 KMT2A (0.56) MAOBMAPK1L3MBTL1ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-8829058-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2014-09-09 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP disclosed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 MAOB 3406/4885PPARA 1930/4885PPARG 2231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.